JP2009536620A - 医薬組み合わせ物 - Google Patents

医薬組み合わせ物 Download PDF

Info

Publication number
JP2009536620A
JP2009536620A JP2009507151A JP2009507151A JP2009536620A JP 2009536620 A JP2009536620 A JP 2009536620A JP 2009507151 A JP2009507151 A JP 2009507151A JP 2009507151 A JP2009507151 A JP 2009507151A JP 2009536620 A JP2009536620 A JP 2009536620A
Authority
JP
Japan
Prior art keywords
group
compound
hydrogen
hydrocarbyl
hydroxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2009507151A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009536620A5 (enExample
Inventor
ニール、トーマス、トンプソン
ジョン、フランシス、ライアンズ
ロバート、ジョージ、ボイル
カイラ、メリオム、グリムショー
ミシェル、ドーン、ガレット
イアン、コリンズ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cancer Research Technology Ltd
Astex Therapeutics Ltd
Original Assignee
Cancer Research Technology Ltd
Astex Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0608172A external-priority patent/GB0608172D0/en
Priority claimed from GB0608178A external-priority patent/GB0608178D0/en
Application filed by Cancer Research Technology Ltd, Astex Therapeutics Ltd filed Critical Cancer Research Technology Ltd
Publication of JP2009536620A publication Critical patent/JP2009536620A/ja
Publication of JP2009536620A5 publication Critical patent/JP2009536620A5/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
JP2009507151A 2006-04-25 2007-04-25 医薬組み合わせ物 Withdrawn JP2009536620A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0608172A GB0608172D0 (en) 2006-04-25 2006-04-25 Pharmaceutical compounds
GB0608178A GB0608178D0 (en) 2006-04-25 2006-04-25 Pharmaceutical compounds
PCT/GB2007/001502 WO2007125310A2 (en) 2006-04-25 2007-04-25 Pharmaceutical combinations of pk inhibitors and other active agents

Publications (2)

Publication Number Publication Date
JP2009536620A true JP2009536620A (ja) 2009-10-15
JP2009536620A5 JP2009536620A5 (enExample) 2010-06-17

Family

ID=38458013

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009507151A Withdrawn JP2009536620A (ja) 2006-04-25 2007-04-25 医薬組み合わせ物

Country Status (4)

Country Link
US (1) US20090082370A1 (enExample)
EP (1) EP2037931A2 (enExample)
JP (1) JP2009536620A (enExample)
WO (1) WO2007125310A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023507188A (ja) * 2019-12-19 2023-02-21 インペリアル・カレッジ・イノベーションズ・リミテッド 白金耐性がんの治療に有用な１ｈ－ピラゾロ［３，４－ｄ］ピリミジン化合物

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY179032A (en) 2004-10-25 2020-10-26 Cancer Research Tech Ltd Ortho-condensed pyridine and pyrimidine derivatives (e.g.purines) as protein kinase inhibitors
US9512125B2 (en) 2004-11-19 2016-12-06 The Regents Of The University Of California Substituted pyrazolo[3.4-D] pyrimidines as anti-inflammatory agents
KR101499783B1 (ko) 2006-04-04 2015-03-09 더 리젠트스 오브 더 유니이버시티 오브 캘리포니아 키나제 길항물질
WO2007125321A2 (en) 2006-04-25 2007-11-08 Astex Therapeutics Limited Purine and deazapurine derivatives as pharmaceutical compounds
US8227603B2 (en) * 2006-08-01 2012-07-24 Cytokinetics, Inc. Modulating skeletal muscle
EP2666777A1 (en) 2006-08-02 2013-11-27 Cytokinetics, Inc. Certain chemical entities having an imidazo<4,5-b>pyrazin-2(3H)-one core, compositions and methods
US8299248B2 (en) * 2006-08-02 2012-10-30 Cytokinetics, Incorporated Certain 1H-imidazo[4,5-b]pyrazin-2(3H)-ones and 1H-imidazo[4,5-b]pyrazin-2-ols and methods for their use
AR064415A1 (es) * 2006-12-21 2009-04-01 Cancer Rec Tech Ltd Derivados de pirrolo-piperidinas y purinas,composiciones farmaceuticas que los contienen y usos en trastornos y/o enfermedades mediadas por pka y pkb.
EP2139478A4 (en) * 2007-03-30 2010-05-05 Cytokinetics Inc CHEMICAL ENTITIES, COMPOSITIONS AND METHODS
UA99284C2 (ru) 2007-05-11 2012-08-10 Елі Ліллі Енд Компані ИНГИБИТОРЫ р70 S6-КИНАЗЫ
US20110160232A1 (en) 2007-10-04 2011-06-30 Pingda Ren Certain chemical entities and therapeutic uses thereof
AU2008309383B2 (en) 2007-10-11 2012-04-19 Astrazeneca Ab Pyrrolo [2, 3 -D] pyrimidin derivatives as protein kinase B inhibitors
AU2009204483B2 (en) 2008-01-04 2014-03-13 Intellikine, Llc Certain chemical entities, compositions and methods
US8193182B2 (en) 2008-01-04 2012-06-05 Intellikine, Inc. Substituted isoquinolin-1(2H)-ones, and methods of use thereof
JP5547099B2 (ja) 2008-03-14 2014-07-09 インテリカイン， エルエルシー キナーゼ阻害剤および使用方法
US8993580B2 (en) 2008-03-14 2015-03-31 Intellikine Llc Benzothiazole kinase inhibitors and methods of use
US8193202B2 (en) 2008-04-21 2012-06-05 Lexicon Pharmaceuticals, Inc. LIMK2 inhibitors, compositions comprising them, and methods of their use
AR071717A1 (es) 2008-05-13 2010-07-07 Array Biopharma Inc Pirrolo[2,3-b]piridinas inhibidoras de quinasas chk1 y chk2,composiciones farmaceuticas que las contienen,proceso para prepararlas y uso de las mismas en el tratamiento y prevencion del cancer.
US20110224223A1 (en) 2008-07-08 2011-09-15 The Regents Of The University Of California, A California Corporation MTOR Modulators and Uses Thereof
MX2011000216A (es) 2008-07-08 2011-03-29 Intellikine Inc Inhibidores de cinasa y metodos para su uso.
WO2010036380A1 (en) 2008-09-26 2010-04-01 Intellikine, Inc. Heterocyclic kinase inhibitors
WO2010045542A2 (en) 2008-10-16 2010-04-22 The Regents Of The University Of California Fused ring heteroaryl kinase inhibitors
US8476431B2 (en) 2008-11-03 2013-07-02 Itellikine LLC Benzoxazole kinase inhibitors and methods of use
AR074072A1 (es) 2008-11-11 2010-12-22 Lilly Co Eli Compuesto de imidazol -piperidin -pirrol-pirimidin-6-ona, composicion farmaceutica que lo comprende y su uso para preparar un medicamento util para tratar el glioblastoma multiforme
WO2010129816A2 (en) 2009-05-07 2010-11-11 Intellikine, Inc. Heterocyclic compounds and uses thereof
EP2789615B1 (en) 2009-08-11 2017-05-03 Bristol-Myers Squibb Company Azaindazoles as Btk kinase modulators and use thereof
WO2011047384A2 (en) 2009-10-16 2011-04-21 The Regents Of The University Of California Methods of inhibiting ire1
JP5951600B2 (ja) 2010-05-21 2016-07-13 インフィニティー ファーマシューティカルズ， インコーポレイテッド キナーゼ調節のための、化合物、組成物および方法
US8901133B2 (en) 2010-11-10 2014-12-02 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
JP5927201B2 (ja) 2010-12-16 2016-06-01 カルチャン リミテッド Ａｓｋ１阻害ピロロピリミジン誘導体
KR20180080358A (ko) 2011-01-10 2018-07-11 인피니티 파마슈티칼스, 인코포레이티드 이소퀴놀린온 및 이의 고체 형태의 제조 방법
JP6130305B2 (ja) 2011-02-23 2017-05-17 インテリカイン， エルエルシー キナーゼ阻害剤の組み合わせおよびそれらの使用
BR112013025410A2 (pt) 2011-04-01 2016-12-20 Astrazeneca Ab tratamento terapêutico
WO2013010015A2 (en) 2011-07-13 2013-01-17 Cytokinetics, Inc. Combination als therapy
EP2734530A1 (en) 2011-07-19 2014-05-28 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
CN103930422A (zh) 2011-07-19 2014-07-16 无限药品股份有限公司 杂环化合物及其用途
CN103998442B (zh) 2011-08-29 2016-09-14 无限药品股份有限公司 杂环化合物及其用途
MX370814B (es) 2011-09-02 2020-01-08 Univ California Pirazolo[3,4-d]pirimidinas sustituidas y usos de las mismas.
US8809372B2 (en) 2011-09-30 2014-08-19 Asana Biosciences, Llc Pyridine derivatives
US9199975B2 (en) 2011-09-30 2015-12-01 Asana Biosciences, Llc Biaryl imidazole derivatives for regulating CYP17
WO2013062945A1 (en) * 2011-10-24 2013-05-02 Glaxosmithkline Intellectual Property Development Limited Chemical compounds
CA2856646C (en) 2011-11-30 2020-01-14 Astrazeneca Ab Combination treatment of cancer
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
AU2013204533B2 (en) 2012-04-17 2017-02-02 Astrazeneca Ab Crystalline forms
US8828998B2 (en) 2012-06-25 2014-09-09 Infinity Pharmaceuticals, Inc. Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors
WO2014052669A1 (en) 2012-09-26 2014-04-03 The Regents Of The University Of California Modulation of ire1
IL291945B2 (en) 2012-11-01 2025-11-01 Infinity Pharmaceuticals Inc Treatment of cancers using pi3 kinase isoform modulators
US9481667B2 (en) 2013-03-15 2016-11-01 Infinity Pharmaceuticals, Inc. Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
WO2015051241A1 (en) 2013-10-04 2015-04-09 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
MX389256B (es) 2013-10-04 2025-03-20 Infinity Pharmaceuticals Inc Compuestos heterociclicos y usos de los mismos.
EP4066834A1 (en) 2014-03-19 2022-10-05 Infinity Pharmaceuticals, Inc. Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders
US20150320755A1 (en) 2014-04-16 2015-11-12 Infinity Pharmaceuticals, Inc. Combination therapies
WO2016054491A1 (en) 2014-10-03 2016-04-07 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
CN108349985A (zh) 2015-09-14 2018-07-31 无限药品股份有限公司 异喹啉酮的固体形式、其制备方法、包含其的组合物及其使用方法
US10759806B2 (en) 2016-03-17 2020-09-01 Infinity Pharmaceuticals, Inc. Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as PI3K kinase inhibitors
WO2017214269A1 (en) 2016-06-08 2017-12-14 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
CA3028718A1 (en) 2016-06-24 2017-12-28 Infinity Pharmaceuticals, Inc. Combination therapies

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY179032A (en) * 2004-10-25 2020-10-26 Cancer Research Tech Ltd Ortho-condensed pyridine and pyrimidine derivatives (e.g.purines) as protein kinase inhibitors
UY29177A1 (es) * 2004-10-25 2006-05-31 Astex Therapeutics Ltd Derivados sustituidos de purina, purinona y deazapurina, composiciones que los contienen métodos para su preparación y sus usos

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023507188A (ja) * 2019-12-19 2023-02-21 インペリアル・カレッジ・イノベーションズ・リミテッド 白金耐性がんの治療に有用な１ｈ－ピラゾロ［３，４－ｄ］ピリミジン化合物
JP7740804B2 (ja) 2019-12-19 2025-09-17 インペリアル・カレッジ・イノベーションズ・リミテッド 白金耐性がんの治療に有用な１ｈ－ピラゾロ［３，４－ｄ］ピリミジン化合物

Also Published As

Publication number Publication date
WO2007125310A3 (en) 2008-03-13
WO2007125310A2 (en) 2007-11-08
US20090082370A1 (en) 2009-03-26
EP2037931A2 (en) 2009-03-25

Similar Documents

Publication Publication Date Title
JP2009536620A (ja) 医薬組み合わせ物
JP5721949B2 (ja) 複合薬剤
JP5523829B2 (ja) 複合薬剤
JP5528807B2 (ja) 複合薬剤
EP3066101B1 (en) Combination therapy for cancer using bromodomain and extra-terminal (bet) protein inhibitors
JP6280546B2 (ja) ジアンヒドロガラクチトール、ジアセチルジアンヒドロガラクチトール、ジブロモズルシトール、又はこれらの類似体若しくは誘導体を用いた、遺伝子多型又はａｈｉ１の調節不全若しくは変異を有する患者におけるチロシンキナーゼインヒビター抵抗性悪性腫瘍を処置するための方法
MX2007008809A (es) Combinaciones de inhibidores de pirazol cinasa y otros agentes antitumor.
JP2009536186A (ja) 癌処置のためのジアゾール誘導体の医薬組合せ
JP2010505931A (ja) 複合薬剤
JP2019135268A (ja) 準最適に投与された化学化合物の治療的有効性
US20100021420A1 (en) Combinations of pyrazole derivatives for the inhibition of cdks and gsk&#39;s
JP2009542608A (ja) 医薬組合せ剤
CN105579044A (zh) 双脱水半乳糖醇及其类似物与衍生物用于治疗复发性恶性神经胶瘤或进行性继发脑瘤的用途
CN106659765A (zh) 二脱水半乳糖醇及其类似物或衍生物用于治疗非小细胞肺癌和卵巢癌的用途
CN112867512A (zh) 联合疗法
US8541461B2 (en) Pharmaceutical combinations comprising pyrazole derivatives as protein kinase modulators
CN113194952A (zh) Hdm2-p53相互作用抑制剂和bcl2抑制剂的组合及其治疗癌症的用途
CN101484173A (zh) Pk抑制剂与其他活性药的药物组合
HK40106272A (zh) 组合疗法中的egfr抑制剂和perk活化剂及其用於治疗癌症的用途
HK1224581A1 (en) Use of dianhydrogalactitol and analogs and derivatives thereof to treat recurrent malignant glioma or progressive secondary brian tumor

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100426

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20100426

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20120423

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20120423